About me
Laura Cooper is Head of Corporate Communications at Day One Biopharmaceuticals, a commercial-stage company focused on advancing first- or best-in-class medicines for childhood and adult diseases with equal intensity. Most recently, Laura led communications around the launch of the company’s first drug approval for the most common type of pediatric brain cancer. She has 25+ years of experience leading corporate and product communications for innovative life sciences and diagnostic public companies, with a passion for improving the lives of those affected by cancer.
Prior to Day One, Laura led corporate communications at Adaptive Biotechnologies during the COVID pandemic for the launch of T-Detect, a next-generation sequencing based test to assess the T cell immune response to the virus. She has also previously developed and executed strategic integrated communications programs at Celgene, Juno Therapeutics and Genzyme. Laura started her career on the agency side at Manning, Selvage & Lee after earning a journalism degree from The Pennsylvania State University.
Laura is based in Seattle with her husband Todd and their three children.
